The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).
Nephrogenic diabetes insipidus (NDI) is a genetic disease. Patients with this disease make large amounts of urine because their kidneys don't hold on to water. The large amount of urine means that patients need to urinate very frequently. They are also at increased risk for dehydration if they don't drink enough. The large amount of urine can sometimes damage their bladders and kidneys. There are some medicines that may help these patients urinate less, but they are not very effective. There is evidence in animal studies that a medication called metformin may help patients with NDI urinate less.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
2
Metformin 500 mg pill dispensed once orally
Childen's Healthcare of Atlanta
Atlanta, Georgia, United States
Emory University Hospital - Atlanta Clinical and Translational Science Institute (ACTSI)
Atlanta, Georgia, United States
Emory University Hospital
Atlanta, Georgia, United States
Change in mean urine osmolality
Urine osmolality is a measure of urine concentration. Urine osmolality will be measured using a Wescor vapor pressure osmometer. A normal range for urine osmolality is approximately 500-850 mOsm/kg water. Change is the difference in average osmolality from baseline to 7 hours.
Time frame: Baseline, 7 hours
Change in mean urine volume
Urine volume is a measure of fluid balance. Change from baseline in average volume of urine collected from baseline to 7 hours.
Time frame: Baseline, 7 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.